Our findings uncover a novel regulatory mechanism of ADAM9 as a transcriptional regulator in angiogenesis and highlight ADAM9 as a promising therapeutic target for ESCC treatment. This evidence concerns the gene ADAM9 and esophageal squamous cell carcinoma.